Drug Approval | December 08, 2023
Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
The esteemed duo perfectly embody the brand's core values of family, love, and the special bond we share with our pets
The new ECO grade is made using renewable feedstock
The product is expected to be launched in FY25
South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution
Subscribe To Our Newsletter & Stay Updated
